{"preliminary_commentary":{"by_channel":{"x_thread":8,"podcast":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04256421\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"SKYSCRAPER-02","nct_id":"NCT04256421","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=skyscraper-02-nct04256421. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SKYSCRAPER-02","arms":[{"description":"Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.","label":"Placebo + Atezolizumab + CE","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.","label":"Tiragolumab + Atezolizumab + CE","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-07-31","type":"ACTUAL"},"conditions":["Small Cell Lung Cancer"],"enrollment":{"count":490,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tiragolumab","otherNames":["MTIG7192A"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Etoposide","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-03","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-09-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)","timeFrame":"From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)"},{"measure":"Overall Survival (OS) in the PAS","timeFrame":"From randomization to death from any cause (up to approximately 24 months)"}],"references":[{"citation":"Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.","pmid":"37976444","type":"DERIVED"}],"start_date":{"date":"2020-02-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04256421"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/skyscraper-02-nct04256421"}